Supplementary Online Content

Richter S, Winzeck S, Kornaropoulos EN, et al; Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury Magnetic Resonance Imaging (CENTER-TBI MRI) Substudy Participants and Investigators. Neuroanatomical substrates and symptoms associated with magnetic resonance imaging of patients with mild traumatic brain injury. *JAMA Netw Open*. 2021;4(3):e210994. doi:10.1001/jamanetworkopen.2021.0994

eFigure 1. Flowchart of Patients Included in the Analysis
eTable 1. Overview of Statistical Methods
eTable 2. Comparison of Patients With and Without Data Available for Each Analysis
eTable 3. Comparison of Lesions Visible on CT vs MR1
eTable 4. Comparison of Volumes Between Patients and Controls
eTable 5. Sensitivity Analysis of Symptom Evolution
eTable 6. Components of the Outcome Models
eTable 7. Sensitivity Analysis of Outcome Models
eFigure 2. Analysis With and Without Patients Who Have Mass Lesions on CT

This supplementary material has been provided by the authors to give readers additional information about their work.
Structural MRI sequences included T1 weighted, T2 weighted, fluid-attenuated inversion recovery and susceptibility weighted imaging.
### eTable 1. Overview of Statistical Methods

| Question                                                                 | Analysis type | Brain regions included                        | Statistical test          | Detailed description                                                                                                                                                                                                                                                                                                                                 |
|--------------------------------------------------------------------------|---------------|-----------------------------------------------|---------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1. Did the incidence of radiologically visible lesions differ between MR1 and MR2? | univariate    | All 10 lesion types                            | McNemar’s test for paired categorical data | -                                                                                                                                                                                                                                                                                                                                              |
| 2. Within patients, did the overall volumetric composition of brain ROIs change from MR1 to MR2? | multivariate  | All 15 ROIs (grey and white matter)           | Two-tailed Hotelling’s one-sample T2 test | We performed a compositional data analysis as described by Aitchinson. In short, first the within-patient change of each ROI relative to the patient’s intracranial volume (“perturbation”) is calculated. To account for the correlation between ROIs, all perturbations for each patient were transformed using an additive log ratio (alr) resulting in one air vector per patient. To decide whether there is a compositional change between MR1 and MR2, we tested whether the mean of all alr vectors differed from zero using the Hotelling’s one-sample $T^2$ test for multivariate data. Note that since serial scans of the same patient were always performed on the same scanner, there were no scanner differences to adjust for. |
| 3. Within patients, did individual ROIs change in volume between MR1 and MR2 (or MR2 and MR3)? | univariate    | All 15 ROIs (grey and white matter)           | two-tailed one-sample t-test | For each ROI, the within-patient change was summarised in a single value as log(Volume on MR2/Volume on MR1) negating the need for a two-sample or paired t-test. The one-sample t-test assessed whether the mean change of all patients differed significantly from zero. The transformation into a log-ratio also ensured that data was normally distributed. Note that since serial scans of the same patient were always performed on the same scanner, there were no scanner differences to adjust for. |
| 4. Did ROI volumes differ between patients and controls at MR1 (or at MR2 or at MR3)? | univariate    | Those 3 ROIs that changed between MR1 and MR2 | mixed model                | ROI volume was first normalised for each person’s total intracranial volume (by taking the ratio ROI/total intracranial volume) and then modelled as follows: Log(Volume) ~ group + age + sex + (1|scanner), where “group” categorised each person as either patient or control. We tested if “group” was significant according to p-values generated via Satterthwaite’s degrees of freedom method (package lmerTest 3.1-2). Note that “scanner” refers to individual machines, not just scanner models, so that there are no residual site effects even if two sites used the same model. Assumptions were tested using diagnostic plots. |
| 5. Did FA (or MD) change in individual tracts between MR1 and MR2?        | univariate    | All 72 white matter tracts                    | Two-tailed one sample t-test | For each tract, the within-patient change was summarised in a single value as log(FA on MR2/FA on MR1) negating the need for a two-sample or paired t-test. This transformation into a logratio also ensured that data was normally distributed. The analogous method was used for MD.                                                                 |
| 6. Did individual tracts differ from controls in their FA (or MD) values? | univariate    | Those 13 tracts that changed between MR1 and MR2 plus | mixed model                | FA ~ group + age + sex + (1|scanner), where “group” categorised each person as either patient or control. We tested if “group” was significant according to p-values generated via Satterthwaite’s degrees of freedom method (package lmerTest 3.1-2). The analogous method was used for MD. Note that “scanner” refers to individual machines, not just |
|   | corpus callosum |   | scanner models, so that there are no residual site effects even if two sites used the same model. Assumptions were tested using diagnostic plots. |
|---|---|---|---|
| 7. | Which of the three phenotypes best describes the DTI changes between MR1 and MR2 for each patient? | bivariate | Those 13 tracts that changed between MR1 and MR2 | k-means clustering | For each tract, the within-patient change was summarised in a single value as log(FA on MR2/FA on MR1). For each patient these 13 single values were added to provide a summary measure of FA change in that patient. The analogous method was used for MD. Clusters were based on two variables: the summary FA change and the summary MD change. The log-ratio transformation ensured both variables are on the same scale. |
| 8. | How did the three phenotypes differ from controls at MR1 (or MR2)? | univariate | Those 13 tracts that changed between MR1 and MR2 | mixed model | We defined the first model as FA ~ group + age + sex + (1|scanner), where "group" categorised each person as either control, pseudonormalisation-phenotype, minimal change-phenotype or progressive injury-phenotype. To decide if "group" had a significant effect we compared the first model with FA ~ age + sex + (1|scanner) using the Chi-squared test. Since "group" had a significant effect for all tracts, p-values were generated via Satterthwaite’s degrees of freedom method (package lmerTest 3.1-2) for the coefficients of each phenotype. For each phenotype p-values were corrected using a false discovery rate threshold of 5% and the number of tracts counted that significantly differed from controls. Assumptions were tested using diagnostic plots. |
| 9. | Did initial mTBI symptoms at the time of MR1 differ between phenotypes? | univariate | n/a | ANOVA | Continuous y-variable: RPQ scores at MR1, Categorical x-variable: phenotype. Assumptions were tested using diagnostic plots. |
| 10. | Did symptoms progress differently in different phenotypes? | univariate | n/a | ANOVA | Continuous y-variable: ΔRPQ score (i.e. RPQ at MR2 minus RPQ at MR1), Categorical x-variable: phenotype. Assumptions were tested using diagnostic plots. |
| 11. | Is imaging associated with clinical outcome? | univariate | All 72 white matter tracts | logistic regression | The y-variable was binary: favorable recovery (GOSE = 8) vs. unfavorable recovery (GOSE < 8). The x-variables included age (continuous), sex (binary) and, where appropriate, "lesion presence" obtained from structured radiology reports, "WM volume" obtained from T1 imaging, and "fa tracts", "md tracts" and "both tracts" from DTI imaging. "Lesion presence" is a binary variable indicating the presence or absence of any visible lesion on any available sequence. "WM volume" is a continuous variable describing by how many standard deviations the patient's cerebral WM volume (normalised for their total brain volume) deviated from the mean of controls scanned on the same machine. The DTI variables where nominal and counted how many of the 72 tracts in each patient where abnormal with respect to only FA, only MD or both. Abnormal meant >2SD below (for FA) or above (for MD) the control mean. This binary classification resulted in better model performance than classifying FA (or MD) as high/normal/low and allowed the inclusion of the variable "both tracts" without resulting in multicollinearity as measured by the generalized variance-inflation factor corrected by the number of degrees of freedom. |
GVIF^{1/(2Df)} with a threshold of 2 (analogous of VIF = 4). Model assumptions were tested using diagnostic plots, the Box-Tidwell test and the GVIF.

| Question                                                                 | Value | Value | Statistical measure(s)                                      |
|--------------------------------------------------------------------------|-------|-------|------------------------------------------------------------|
| 12. Which imaging timepoint and sequences is more closely associated with outcome? | n/a   | n/a   | AUC, CV, AIC                                               |
| 13. Are conclusions from Q10-12 robust even though patients with missing outcome data were excluded from the analyses? | n/a   | n/a   | Sensitivity analysis (best- and worst-case scenario)       |

The above logistic regression models were compared using three measures: the area under the receiver operating characteristic curve (AUC), ten-fold cross-validation (CV) and the Akaike information criterion (AIC). To obtain the AUC, observed and predicted outcome was compared for all patients with available data. Two AUCs were compared using a paired DeLong’s test. The CV accuracy is the average accuracy of ten measures obtained by randomly splitting the data into ten folds and repeatedly training the model on nine folds and testing it on the remaining fold. When comparing two models based on AIC, we considered a model to fit the data significantly better if its AIC was at least 2 units lower than that of the alternative model.

Sensitivity analysis for Q10: Some patients had been excluded from the complete-case analysis as they were missing ΔRPQ data. For the worst-case scenario, we assumed all 10 patients had deteriorated and imputed a ΔRPQ of +5 (the median observed in the progressive injury phenotype). For the best-case scenario, we assumed all 10 patients had improved and imputed a ΔRPQ of -4.5 (the median observed in the minimal change phenotype). An ANOVA as per Q10 was then conducted for both scenarios.

Sensitivity analysis for Q11-12: Some patients were excluded from the predictions models as they were missing GOSE data. For these patients an incomplete recovery was imputed for the worst-case scenario and a complete recovery for the best-case scenario. Logistic regression and an assessment of model performance was then conducted as per Q11 and Q12.

MR1/MR2/MR3 = Magnetic resonance scan performed within 72h/at 2–3 weeks/at 3-months after injury, ROI = Region of interest, FA = fractional anisotropy, MD = mean diffusivity, WM = white matter, SD = standard deviation. Statistical significance was determined by applying a false discovery rate threshold of 5% within each question.
### eTable 2. Comparison of Patients With and Without Data Available for Each Analysis

| Analysis                                                                 | Structural | DTI evolution between scans | Symptom evolution between scans | Outcome analysis |
|--------------------------------------------------------------------------|------------|-----------------------------|---------------------------------|------------------|
|                                                                          | Overall  (n=81) | Included  (n=63) | Excluded  (n=18) | Raw p-value | Included  (n=53) | Excluded  (n=28) | Raw p-value | Included  (n=65) | Excluded  (n=16) | Raw p-value |
| **Age**                                                                 |             |                            |                                |               |                 |                   |             |                 |                   |             |
| Median (Q1-Q3)                                                          | 45 (24 - 59) | 47 (27.5 - 59) | 36 (22 - 56.8) | 0.30        | 46 (23 - 59)  | 42 (28 - 56.2) | 0.77        | 47 (25 - 59)  | 36 (20.5 - 56.2) | 0.22        |
| **Sex**                                                                 |             |                            |                                |               |                 |                   |             |                 |                   |             |
| F                                                                       | 24 (30 %)   | 18 (29 %)                  | 6 (33 %)               | 0.77        | 16 (30 %)     | 8 (29 %)        | 1.00        | 18 (28 %)     | 6 (38 %)         | 0.54        |
| M                                                                       | 57 (70 %)   | 45 (71 %)                  | 12 (67 %)              |             | 37 (70 %)     | 20 (71 %)       |             | 47 (72 %)     | 10 (62 %)        |             |
| **Education**                                                           |             |                            |                                |               |                 |                   |             |                 |                   |             |
| Completed degree                                                        | 33 (41 %)   | 29 (46 %)                  | 4 (22 %)                | 0.09        | 24 (45 %)     | 9 (32 %)        | 0.17        | 28 (43 %)     | 5 (31 %)         | 0.53        |
| Current degree                                                          | 1 (1 %)     | 0 (0 %)                    | 1 (6 %)                 |             | 0 (0 %)       | 1 (4 %)         |             | 1 (2 %)       | 0 (0 %)          |             |
| High school                                                             | 25 (31 %)   | 20 (32 %)                  | 5 (28 %)                |             | 16 (30 %)     | 9 (32 %)        |             | 21 (32 %)     | 4 (25 %)         |             |
| Post-high school trained                                                | 11 (14 %)   | 10 (16 %)                  | 1 (6 %)                 |             | 10 (19 %)     | 1 (4 %)         |             | 9 (14 %)      | 2 (12 %)         |             |
| Primary school                                                          | 4 (5 %)     | 2 (3 %)                    | 2 (11 %)                |             | 2 (4 %)       | 2 (7 %)         |             | 2 (3 %)       | 2 (12 %)         |             |
| Missing                                                                 | 7 (8.6 %)   | 2 (3.2 %)                  | 5 (27.8%)              |             | 1 (1.9 %)     | 6 (21.4 %)      |             | 4 (6.2 %)     | 3 (18.8 %)       |             |
| **Mechanism of Injury**                                                 |             |                            |                                |               |                 |                   |             |                 |                   |             |
| Acc-/deceleration                                                       | 10 (12 %)   | 7 (11 %)                   | 3 (17 %)                | 0.75        | 6 (11 %)      | 4 (14 %)        | 0.62        | 8 (12 %)      | 2 (12 %)         | 0.80        |
| Blow to head                                                            | 7 (9 %)     | 7 (11 %)                   | 0 (0 %)                 |             | 6 (11 %)      | 1 (4 %)         |             | 7 (11 %)      | 0 (0 %)          |             |
| Fall from height                                                        | 21 (26 %)   | 15 (24 %)                  | 6 (33 %)                |             | 11 (21 %)     | 10 (36 %)       |             | 16 (25 %)     | 5 (31 %)         |             |
| Ground level fall                                                       | 19 (23 %)   | 15 (24 %)                  | 4 (22 %)                |             | 13 (25 %)     | 6 (21 %)        |             | 16 (25 %)     | 3 (19 %)         |             |
| Head against object                                                     | 11 (14 %)   | 9 (14 %)                   | 2 (11 %)                |             | 7 (13 %)      | 4 (14 %)        |             | 8 (12 %)      | 3 (19 %)         |             |
| Multimechanistic                                                        | 13 (16 %)   | 10 (16 %)                  | 3 (17 %)                |             | 10 (19 %)     | 3 (11 %)        |             | 10 (15 %)     | 3 (19 %)         |             |
| **GCS**                                                                 |             |                            |                                |               |                 |                   |             |                 |                   |             |
| Median (Q1-Q3)                                                          | 15 (15 - 15) | 15 (15 - 15) | 15 (14.2 - 15) | 0.39        | 15 (15 - 15)  | 15 (14 - 15) | 0.20        | 15 (15 - 15)  | 15 (14 - 15) | 0.07        |
| **ISS**                                                                 |             |                            |                                |               |                 |                   |             |                 |                   |             |
| Median (Q1-Q3)                                                          | 8.5 (4 - 16.2) | 8.0 (4 - 10) | 17 (9 - 27) | 0.005        | 5.0 (4 - 9)  | 20 (9 - 28) | <0.001      | 8.0 (4 - 10)  | 17 (9 - 27) | 0.02        |
| Missing                                                                 | 1 (1.2%)    | 0 (0%)                    | 1 (5.6%)                |             | 0 (0%)       | 1 (3.6%)        |             | 0 (0%)       | 1 (6.2%)         |             |
| **Stratum**                                                             |             |                            |                                |               |                 |                   |             |                 |                   |             |
| ER                                                                      | 42 (52 %)   | 37 (59 %)                  | 5 (28 %)                | 0.06        | 36 (68 %)     | 6 (21 %)        | <0.001      | 36 (55 %)     | 6 (38 %)         | 0.24        |
| Admission                                                               | 30 (37 %)   | 20 (32 %)                  | 10 (56 %)               |             | 17 (32 %)     | 13 (46 %)       |             | 21 (32 %)     | 9 (56 %)         |             |
| ICU                                                                     | 9 (11 %)    | 6 (10 %)                   | 3 (17 %)                |             | 0 (0 %)      | 9 (32 %)        |             | 8 (12 %)      | 1 (6 %)          |             |

©2021 Richter S et al. JAMA Network Open.
| Marshall score | 1 | 2 | 3 | 4 | 5 | 6 |
|---------------|---|---|---|---|---|---|
|               | 57 (70%) | 45 (71%) | 12 (67%) | 0.85 | 41 (77%) | 16 (57%) | 0.11 | 44 (68%) | 13 (81%) | 0.71 |
|               | 18 (22%) | 13 (21%) | 5 (28%) | 10 (19%) | 8 (29%) | 16 (25%) | 2 (12%) |
|               | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
|               | 1 (1%) | 1 (2%) | 0 (0%) | 0 (0%) | 1 (4%) | 1 (2%) | 0 (0%) |
|               | 5 (6%) | 4 (6%) | 1 (6%) | 2 (4%) | 3 (11%) | 4 (6%) | 1 (6%) |
| CWM ratio     | Median (Q1-Q3) | 0.98 (0.96 - 1) | 0.99 (0.97 - 0.99) | 0.61 (0.97 - 0.99) | 0.98 (0.96 - 1) | 0.99 (0.97 - 0.99) | 0.60 (0.96 - 1) | 0.98 (0.97 - 0.99) | 0.70 (0.60 - 0.70) |
| Phenotype     | Minimal change | 33 (41%) | 33 (52%) | 0 (0%) | 1.00 (11%) | 3 (11%) | 0.09 (12%) | 29 (45%) | 4 (25%) | 0.18 (5.2 - 0.5) |
|               | Progressive injury | 8 (10%) | 8 (13%) | 0 (0%) | 5 (9%) | 3 (11%) | 8 (12%) | 0 (0%) |
|               | Pseudonormalisation | 22 (27%) | 22 (35%) | 0 (0%) | 18 (34%) | 4 (14%) | 22 (34%) | 0 (0%) |
|               | Missing | 18 (22.2%) | 0 (0%) | 18 (100%) | 0 (0%) | 18 (64.3%) | 6 (9.2%) | 12 (75.0%) |
| ΔRPQ          | Median (Q1-Q3) | -1.0 (-7 - 5) | -2.0 (-7 - 5) | -1.0 (-1 - 3) | 0.46 (0.46) | -2.0 (-7 - 5) | -1.0 (-1 - 3) | 0.46 (0.46) | -1.0 (-5.2 - 0.5) | 0.77 (0.77) |
|               | Missing | 24 (29.6%) | 10 (15.9%) | 14 (77.8%) | 0 (0%) | 24 (85.7%) | 16 (24.6%) | 8 (50.0%) |
| GOSE          | Median (Q1-Q3) | 7.0 (6.5 - 8) | 8.0 (7 - 8) | 7.0 (6 - 7.2) | 0.07 (0.07) | 8.0 (7 - 8) | 7.0 (6 - 8) | 0.04 (0.04) | 8.0 (7 - 8) | 6.5 (6 - 7.8) | 0.30 (0.30) |
|               | Missing | 10 (12.3%) | 4 (6.3%) | 6 (33.3%) | 4 (7.5%) | 6 (21.4%) | 0 (0%) | 10 (62.5%) |
| MR1           | Median (Q1-Q3) | 36 (24.7 - 55.2) | 43 (24.2 - 59) | 31 (25 - 42) | 0.19 (23.8 - 59.5) | 40 (25.4 - 49.7) | 34 (25 - 58.6) | 0.67 (22.6 - 33.2) | 30 (22.6 - 33.2) | 0.03 (0.03) |
| MR2           | Median (Q1-Q3) | 17 (14.8 - 21.1) | 16 (14.7 - 20.8) | 20 (18.3 - 21.7) | 0.02 (14.6 - 20.5) | 16 (16.3 - 21.8) | 0.02 (14.8 - 21.2) | 16 (16.3 - 20.4) | 0.57 (0.57) |
| MR3           | Median (Q1-Q3) | 97 (92 - 100) | 96 (91.2 - 99.9) | 99 (95.6 - 100) | 0.75 (91.1 - 99.7) | 96 (96.7 - 100.3) | 99 (91.3 - 99.8) | 97 (94.7 - 99.1) | 0.92 (0.92) |
|               | Missing | 42 (51.9%) | 27 (42.9%) | 15 (83.3%) | 19 (35.8%) | 23 (82.1%) | 28 (43.1%) | 14 (87.5%) |

©2021 Richter S et al. JAMA Network Open.
Data were compared using the Mann-Whitney test for numeric and Fisher’s exact test for categorical data. Reported p-values are unadjusted. Applying a false discovery threshold of 5%, only p-values < 0.001 remained significant and are highlighted in grey. Thus, patients without RPQ data were more severely injured and more commonly required intensive care but had comparable GCS and Marshall scores, suggesting they were untestable due to extra-cranial injuries. Otherwise there was no significant difference between patients with and without available data. “Stratum” indicates whether the patient was discharged from the emergency department (ER), was admitted for standard care (Admission) or intensive care (ICU). GCS = Glasgow Coma Scale score on presentation, ISS = Injury Severity Score on presentation, CWM ratio = ratio of the volume of cerebral white matter on MR2/MR1, Phenotype = pattern of change in DTI parameters between scans, ΔRPQ = difference in Rivermead post-concussion symptoms questionnaire scores at MR2 minus MR1, GOSE = Glasgow Outcome Scale Extended, MR1/MR2/MR3 = serial magnetic resonance scans within 72h/at 2–3 weeks/at 3 months after injury.
### eTable 3. Comparison of Lesions Visible on CT vs MR1

| Abnormality                  | CT positive | CT positive also seen on MR1 | CT positive lesion not seen on MR1 | CT negative | CT negative also negative | MR1 also lesion not seen on CT | MR1 lesion not seen on CT | Raw p-value | FDR |
|------------------------------|-------------|------------------------------|-----------------------------------|-------------|---------------------------|-----------------------------|-----------------------------|-------------|-----|
| **Any Abnormality**          | 24 (100%)   | 18 (75%)                    | 6 (25%)                           | 52 (100%)   | 39 (75%)                  | 13 (25%)                    | 0.17                      |             |     |
| **Mass effect**              |             |                              |                                   |             |                           |                             |                             |             |     |
| Mass > 25cc                  | 5 (100%)    | 2 (40%)                     | 3 (60%)                           | 71 (100%)   | 71 (100%)                 | 0 (0%)                      | 0.25                      |             |     |
| Midline shift                | 2 (100%)    | 1 (50%)                     | 1 (50%)                           | 74 (100%)   | 74 (100%)                 | 0 (0%)                      | 1.00                      |             |     |
| Cisternal compression        | 2 (100%)    | 1 (50%)                     | 1 (50%)                           | 74 (100%)   | 74 (100%)                 | 0 (0%)                      | 1.00                      |             |     |
| **Intra-axial**              |             |                              |                                   |             |                           |                             |                             |             |     |
| Contusion                    | 9 (100%)    | 9 (100%)                    | 0 (0%)                            | 67 (100%)   | 59 (88%)                  | 8 (12%)                      | 0.01                      | sig.        |     |
| Traumatic axonal injury      | 0 (100%)    | 0 (0%)                      | 0 (0%)                            | 76 (100%)   | 57 (75%)                  | 19 (25%)                     | <0.001                    | sig.        |     |
| **Extra-axial**              |             |                              |                                   |             |                           |                             |                             |             |     |
| Epidural haemorrhage         | 4 (100%)    | 3 (75%)                     | 1 (25%)                           | 72 (100%)   | 72 (100%)                 | 0 (0%)                      | 1.00                      |             |     |
| Subdural haemorrhage         | 7 (100%)    | 3 (43%)                     | 4 (57%)                           | 69 (100%)   | 65 (94%)                  | 4 (6%)                      | 1.00                      |             |     |
| Subarachnoid haemorrhage     | 12 (100%)   | 7 (58%)                     | 5 (42%)                           | 64 (100%)   | 59 (92%)                  | 5 (8%)                      | 1.00                      |             |     |
| **Other**                    |             |                              |                                   |             |                           |                             |                             |             |     |
| Skull fracture               | 15 (100%)   | 0 (0%)                      | 15 (100%)                         | 61 (100%)   | 61 (100%)                 | 0 (0%)                      | <0.001                    | sig.        |     |
| Intraventricular haemorrhage | 3 (100%)    | 2 (67%)                     | 1 (33%)                           | 73 (100%)   | 67 (92%)                  | 6 (8%)                      | 0.13                      |             |     |

81 patients received a computed tomography scan (CT) within 24h and a magnetic resonance scan (MR1) within 72h of their mild traumatic brain injury. The presence of visible lesions was compared between scans using McNemar’s test for categorical data. The column FDR indicates which p-values are statistically significant (sig.) based on a false discovery rate threshold of 5%.
### eTable 4. Comparison of Volumes Between Patients and Controls

| Timepoint | ROI                 | Raw Coefficient | Standard Error | Ratio patient/ control | Unadjusted p-value | FDR-adjusted significance |
|-----------|---------------------|-----------------|----------------|------------------------|--------------------|---------------------------|
| MR1       | Ventricles          | 0.069           | 0.054          | 1.07                   | 0.20               | not sig.                  |
|           | Convexity CSF       | -0.045          | 0.042          | 0.96                   | 0.30               | not sig.                  |
|           | Cerebral white matter | -0.011         | 0.009          | 0.99                   | 0.24               | not sig.                  |
| MR2       | Ventricles          | 0.176           | 0.053          | 1.19                   | 0.001              | significant               |
|           | Convexity CSF       | 0.039           | 0.039          | 1.04                   | 0.31               | not sig.                  |
|           | Cerebral white matter | -0.032         | 0.008          | 0.97                   | 0.00               | significant               |

81 patients with mild traumatic brain injury were compared to healthy controls using mixed models, adjusted for age, sex, scanner and total intracranial volume. Magnetic resonance images were obtained within 72h (MR1) and at 2–3 weeks (MR2) after injury. FDR = false discovery rate with a 5% threshold.
### eTable 5. Sensitivity Analysis of Symptom Evolution

| Phenotype                  | Complete case analysis | Worst-case scenario | Best-case scenario |
|----------------------------|------------------------|---------------------|--------------------|
| Progressive injury         | 5.00 [2.00-5.00]       | 5.00 [4.25-5.00]    | 1.00 [-4.50-5.00]  |
| Minimal change             | -4.50 [-9.25-1.75]     | -3.00 [-7.00-5.00]  | -4.50 [-7.00-1.00] |
| Pseudonormalisation       | 0.00 [-6.25-9.00]      | 3.00 [-4.00-8.25]   | -3.00 [-4.50-8.25] |
| P-value                    | 0.02                   | 0.008               | 0.05               |

Phenotype refers to the imaging phenotype i.e. the way in which diffusion parameters changed between 72h and 2-3 weeks after injury. \( \Delta \text{RPQ} \) score = difference in Rivermead post-concussion symptoms questionnaire scores between 72h and 2-3 weeks, whereby a positive number indicates worsening symptoms and a negative number a reduction in symptoms. Complete case analysis excluded 10 patients for missing \( \Delta \text{RPQ} \) data. The worst case scenario assumed mTBI symptoms in all 10 patients deteriorated, the best case scenario assumed all 10 patients improved. The table shows that even if RPQ data was missing not at random, the association between phenotypes and symptoms persists.
## eTable 6. Components of the Outcome Models

| Timepoint/Sequences | Variable                                      | Odds ratio | 95% CI     | P-value |
|--------------------|-----------------------------------------------|------------|------------|---------|
| **No imaging**     | **Intercept**                                 | 3.26       | 0.86 - 13.7| 0.09    |
|                    | **Age**                                        | 0.97       | 0.94 - 1.00| 0.04    |
|                    | **Female sex**                                | 1.94       | 0.63 - 6.39| 0.26    |
| **MR1**            | **T1 Intercepts**                             | 1.73       | 0.35 - 8.93| 0.50    |
|                    | **Age**                                        | 0.98       | 0.95 - 1.01| 0.26    |
|                    | **Female sex**                                | 1.27       | 0.36 - 4.49| 0.71    |
|                    | **White matter volume**                       | **0.67**   | **0.50 - 0.86**| **0.005**|
| **DTI**            | **Intercept**                                 | 9.8        | 1.81 - 69.78| 0.01    |
|                    | **Age**                                        | 0.95       | **0.91 - 0.99**| **0.02**|
|                    | **Female sex**                                | 1.31       | 0.35 - 5.2 | 0.69    |
|                    | **Tracts with only FA abnormal**               | 0.80       | 0.63 - 0.93| 0.03    |
|                    | **Tracts with only MD abnormal**               | 1.00       | 0.95 - 1.06| 0.88    |
|                    | **Tracts with both FA and MD abnormal**       | 1.06       | 1.00 - 1.13| 0.07    |
| **T1 & DTI**       | **Intercept**                                 | 6.86       | 0.9 - 66.44| 0.07    |
|                    | **Age**                                        | 0.96       | 0.92 - 1.01| 0.12    |
|                    | **Female sex**                                | 0.64       | 0.13 - 3.04| 0.58    |
|                    | **Tracts with only FA abnormal**               | **0.79**   | **0.58 - 0.92**| **0.04**|
|                    | **Tracts with only MD abnormal**               | 0.99       | 0.93 - 1.05| 0.74    |
|                    | **Tracts with both FA and MD abnormal**       | **1.07**   | **1.01 - 1.15**| **0.05**|
|                    | **White matter volume**                       | **0.60**   | **0.4 - 0.82**| **0.004**|
| **MR2**            | **T1 Intercepts**                             | 1.90       | 0.39 - 9.6 | 0.43    |
|                    | **Age**                                        | 0.98       | 0.95 - 1.01| 0.18    |
|                    | **Female sex**                                | 1.54       | 0.47 - 5.2 | 0.48    |
|                    | **White matter volume**                       | 0.86       | 0.67 - 1.07| 0.18    |
| **DTI**            | **Intercept**                                 | 6.07       | 1.23 - 36.25| 0.03    |
|                    | **Age**                                        | **0.96**   | **0.92 - 0.99**| **0.03**|
|                    | **Female sex**                                | 1.78       | 0.5 - 6.84 | 0.38    |
|                    | **Tracts with only FA abnormal**               | 0.91       | 0.80 - 1.00| 0.08    |
|                    | **Tracts with only MD abnormal**               | 1.01       | 0.95 - 1.07| 0.79    |
|                    | **Tracts with both FA and MD abnormal**       | 1.02       | 0.97 - 1.08| 0.37    |
| **T1 & DTI**       | **Intercept**                                 | 3.71       | 0.64 - 24.49| 0.15    |
|                    | **Age**                                        | 0.97       | 0.93 - 1.01| 0.10    |
|                    | **Female sex**                                | 1.37       | 0.35 - 5.54| 0.65    |
|                    | **Tracts with only FA abnormal**               | **0.90**   | **0.79 - 0.99**| **0.06**|
|                    | **Tracts with only MD abnormal**               | 1.00       | 0.94 - 1.06| 0.99    |
|                    | **Tracts with both FA and MD abnormal**       | 1.03       | 0.98 - 1.08| 0.31    |
|                    | **White matter volume**                       | 0.83       | 0.64 - 1.05| 0.13    |
| **MR1**            | **Qualitative only Intercepts**               | 3.52       | 0.85 - 16.5 | 0.09    |
|                    | **Age**                                        | 0.98       | 0.95 - 1.01| 0.14    |
|                    | **Female sex**                                | 1.89       | 0.59 - 6.54| 0.29    |
|                    | **Visible lesion present**                    | 0.39       | 0.13 - 1.11| 0.08    |
| **T1, DTI & Qualitative** | **Intercept**                          | 7.04       | 0.93 - 67.54| 0.07    |
|                    | **Age**                                        | 0.97       | 0.92 - 1.01| 0.16    |
|                    | **Female sex**                                | 0.72       | 0.14 - 3.54| 0.68    |
|                    | **Tracts with only FA abnormal**               | 0.79       | 0.57 - 0.93| 0.05    |
|                    | **Tracts with only MD abnormal**               | 0.99       | 0.93 - 1.05| 0.87    |
|                    | **Tracts with both FA and MD abnormal**       | **1.07**   | **1.01 - 1.15**| **0.04**|
| Timepoint/Sequences | Variable                  | Odds ratio | 95% CI     | P-value |
|---------------------|---------------------------|------------|------------|---------|
|                     | White matter volume       | 0.62       | 0.42 - 0.84| 0.005   |
|                     | Visible lesion present    | 0.44       | 0.10 - 1.83| 0.26    |

Logistic regression was used to identify the association between imaging and the odds of a favorable recovery at three months post-injury, defined as a score on the Glasgow Outcome Scale Extended of no less than 8. MR1 = magnetic resonance imaging obtained within 72h of injury. MR2 = magnetic resonance obtained 2-3 weeks post-injury. White matter volume = the deviation of the patients’ cerebral white matter volume from that of healthy controls scanned on the same machine, whereby the volumes were normalised to each subject's total intracranial volume. DTI = Diffusion tensor imaging. Qualitative = the presence or absence of any visible lesion reported by an expert who reviewed all available sequences (T1 weighted, T2 weighted, fluid-attenuated inversion recovery, susceptibility weighted imaging and DTI). 95% CI = 95% Confidence Interval. In bold are Confidence intervals that do not include 1. P-values are unadjusted. Note that after correction for a false discovery threshold of 5% none of the p-values remain significant.
**eTable 7. Sensitivity Analysis of Outcome Models**

| Timepoint and Sequences | Complete case analysis | Worst-case scenario | Best-case scenario |
|-------------------------|------------------------|---------------------|-------------------|
|                         | AUC (95% CI)           | CV (95% CI)         | AIC               |
|                         | PPV                  | NPV            | AUC (95% CI)       | CV (95% CI)         | AIC | PPV | NPV |
| No imaging              | 0.65 (0.51-0.78)      | 0.50 (0.20-0.81)  | 94 0.53 0.53      | 0.63 (0.50-0.75)    | 0.60 (0.33-0.87)  | 108 | 0.62 | 0.65 |
| MR1                     | 0.76 (0.64-0.88)      | 0.67 (0.35-1.00)  | 83 0.81 0.71      | 0.76 (0.64-0.87)    | 0.68 (0.41-0.95)  | 91 0.76 0.70      | 0.72 (0.6-0.84)    | 0.59 (0.26-0.91)  | 94 0.67 0.58 |
| T1 only                 | 0.76 (0.64-0.88)      | 0.63 (0.41-0.85)  | 84 0.62 0.65      | 0.73 (0.61-0.84)    | 0.58 (0.33-0.84)  | 95 0.57 0.65      | 0.74 (0.63-0.86)   | 0.63 (0.37-0.89)  | 93 0.68 0.68 |
| DTI only                | 0.87 (0.78-0.96)      | 0.73 (0.38-1.00)  | 74 0.79 0.81      | 0.86 (0.77-0.94)    | 0.71 (0.51-0.91)  | 83 0.74 0.79      | 0.84 (0.75-0.93)   | 0.71 (0.33-1.00)  | 85 0.74 0.77 |
| T1 & DTI               | 0.87 (0.78-0.96)      | 0.73 (0.38-1.00)  | 74 0.79 0.81      | 0.86 (0.77-0.94)    | 0.71 (0.51-0.91)  | 83 0.74 0.79      | 0.84 (0.75-0.93)   | 0.71 (0.33-1.00)  | 85 0.74 0.77 |
| MR2                     | 0.67 (0.53-0.8)       | 0.57 (0.32-0.82)  | 91 0.60 0.55      | 0.67 (0.54-0.79)    | 0.59 (0.28-0.9)    | 100 0.59 0.59     | 0.65 (0.52-0.78)   | 0.50 (0.11-0.89)  | 99 0.64 0.59 |
| T1 only                | 0.71 (0.58-0.84)      | 0.59 (0.23-0.96)  | 92 0.66 0.64      | 0.69 (0.56-0.81)    | 0.55 (0.23-0.86)  | 101 0.58 0.62     | 0.71 (0.58-0.83)   | 0.60 (0.22-0.97)  | 99 0.67 0.62 |
| DTI only               | 0.71 (0.58-0.84)      | 0.59 (0.23-0.96)  | 92 0.66 0.64      | 0.69 (0.56-0.81)    | 0.55 (0.23-0.86)  | 101 0.58 0.62     | 0.71 (0.58-0.83)   | 0.60 (0.22-0.97)  | 99 0.67 0.62 |
| T1 & DTI              | 0.75 (0.62-0.87)      | 0.58 (0.21-0.94)  | 92 0.69 0.67      | 0.73 (0.61-0.85)    | 0.61 (0.39-0.82)  | 100 0.69 0.69     | 0.73 (0.61-0.85)   | 0.59 (0.20-0.99)  | 100 0.67 0.68 |
| MR1                     | 0.69 (0.56-0.82)      | 0.6 (0.09-1.00)   | 90 0.68 0.65      | 0.67 (0.55-0.80)    | 0.61 (0.30-0.92)  | 101 0.61 0.64     | 0.69 (0.57-0.82)   | 0.57 (0.14-1.00)  | 98 0.68 0.64 |
| Qualitative only       | 0.69 (0.56-0.82)      | 0.6 (0.09-1.00)   | 90 0.68 0.65      | 0.67 (0.55-0.80)    | 0.61 (0.30-0.92)  | 101 0.61 0.64     | 0.69 (0.57-0.82)   | 0.57 (0.14-1.00)  | 98 0.68 0.64 |
| T1, DTI & Qualitative | 0.87 (0.78-0.96)      | 0.72 (0.37-1.00)  | 74 0.72 0.76      | 0.85 (0.77-0.94)    | 0.71 (0.47-0.95)  | 84 0.76 0.79      | 0.84 (0.75-0.93)   | 0.71 (0.34-1.00)  | 86 0.76 0.73 |
Logistic regression was used to identify the association between imaging and the odds of a favourable recovery at three months post-injury, defined as a score of no less than 8 on the Glasgow Outcome Scale Extended. For the worst-case scenario, patients with missing outcome data were assumed to have had an unfavourable recovery. For the best-case scenario, a favourable recovery was assumed. The “no imaging” model includes only age and sex. All other models contain age and sex plus imaging information. MR1 = magnetic resonance imaging obtained within 72h of injury. MR2 = magnetic resonance obtained 2–3 weeks post-injury. T1 = the variable used was the deviation of the patients’ cerebral white matter volume from that of healthy control scanned on the same machine, whereby the volumes were normalised to each subject’s total intracranial volume. DTI = Diffusion tensor imaging; variables included the number of abnormal tracts with regards to fractional anisotropy, median diffusivity or both compared to healthy controls scanned on the same machine. Qualitative = the presence or absence of any visible lesion reported by an expert who reviewed all available sequences (T1 weighted, T2 weighted, fluid-attenuated inversion recovery, susceptibility weighted imaging and DTI). AUC = Area under the receiver operating characteristic curve. CV = Accuracy of predictive performance obtained from ten-fold cross-validation. 95% CI = 95% confidence interval. AIC = Akaike information criterion, note that lower values indicate better model fit. PPV = Positive predictive value. NPV = Negative predictive value. The table shows that, even if outcome data was missing not at random, MR1 continues to correlate more closely with outcome than MR2, and combining T1 and DTI sequences yields better results than using either sequence alone.
eFigure 2. Analysis With and Without Patients Who Have Mass Lesions on CT

Left-hand panel: original analysis of all mild TBI patients presented as Figure 2 in the main manuscript. Right-hand panel: sensitivity analysis after exclusion of patients with visible mass lesions on their initial computed tomography scan (CT) i.e. a Marshall score of 5 or 6.